$82.6 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VENTYX BIOSCIENCES INC | $25,003,395 | +2.2% | 746,370 | 0.0% | 30.26% | -6.5% | ||
| ICOSAVAX INC | $20,359,322 | -27.0% | 3,510,228 | 0.0% | 24.64% | -33.2% | ||
| Buy | JASPER THERAPEUTICS INC | $15,420,563 | +445.6% | 8,519,648 | +45.6% | 18.66% | +399.1% | |
| HILLEVAX INC | $9,238,997 | -1.2% | 558,923 | 0.0% | 11.18% | -9.6% | ||
| TALS | TALARIS THERAPEUTICS INC | $5,513,299 | +84.3% | 2,932,606 | 0.0% | 6.67% | +68.6% | |
| ELEV | ELEVATION ONCOLOGY INC | $4,503,270 | +100.0% | 2,370,142 | 0.0% | 5.45% | +83.0% | |
| KZR | KEZAR LIFE SCIENCES INC | $2,593,865 | -55.5% | 828,711 | 0.0% | 3.14% | -59.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-04-25
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.